Hepatitis B Vaccine Responsiveness and Clinical Outcomes in HIV Controllers
Open Access
- 21 August 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (8) , e105591
Abstract
Hepatitis B virus (HBV) vaccine responsiveness is associated with reduced risk of AIDS or death in HIV-infected individuals. Although HIV controllers (HIC) typically have favorable immunologic and clinical characteristics compared to non-controllers, vaccine responsiveness has not been studied. In the U.S. Military HIV Natural History Study, HBV vaccine response was defined as antibody to hepatitis B surface antigen (anti-HBs) ≥10 IU/L after last vaccination. For determination of vaccine responsiveness, HIC (n = 44) and treatment-naïve non-controllers (n = 476) were not on highly active antiretroviral therapy (HAART) when vaccinated while treated non-controllers (n = 284) received all HBV vaccine doses during viral load (VL)-suppressive HAART. Progression to AIDS or death was also compared for all HIC (n = 143) and non-controllers (n = 1566) with documented anti-HBs regardless of the timing of HBV vaccination. Positive vaccine responses were more common in HIC (65.9%) compared to HAART-naïve non-controllers (36.6%; P<0.001), but similar to non-controllers on HAART (59.9%; P = 0.549). Factors associated with vaccine response for HIC compared to HAART-naïve non-controllers include HIC status (OR 2.65, 95% CI 1.23–5.89; P = 0.014), CD4 count at last vaccination (OR 1.28, 1.15–1.45 for every 100 cells/uL; P<0.001), and number of vaccine doses administered (OR 0.56, 0.35–0.88; P = 0.011). When HIC were compared to non-controllers on HAART, only CD4 count at last vaccination was significant (OR 1.23, 1.1–1.38 for every 100 cells/uL; P<0.001). The rate of AIDS or death per 100 person/years for HIC compared to non-controllers was 0.14 (95% CI 0–0.76) versus 0.98 (95% CI 0.74–1.28) for vaccine responders and 0 (95% CI 0–2.22) versus 4.11 (95% CI 3.38–4.96) for non-responders, respectively. HIC have improved HBV vaccine responsiveness compared to treatment-naïve non-controllers, but similar to those on VL-suppressive HAART. Progression to AIDS or death can be predicted by HBV vaccine responder status for non-controllers, however these events are rarely observed in HIC.Keywords
This publication has 34 references indexed in Scilit:
- Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adultsVaccine, 2012
- Increased Regulatory T Cell Counts in HIV‐Infected Nonresponders to Hepatitis B Virus VaccineThe Journal of Infectious Diseases, 2010
- Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: Another benefit of HAART in those with preserved CD4 countVaccine, 2009
- Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV‐infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccineHIV Medicine, 2007
- Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccinationVaccine, 2006
- HIV Controllers: A Homogeneous Group of HIV-1--Infected Patients with Spontaneous Control of Viral ReplicationClinical Infectious Diseases, 2005
- Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected PersonsClinical Infectious Diseases, 2005
- The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activationVirology, 2004
- The CD40 Antigen and its LigandAnnual Review of Immunology, 1994
- 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.1992